Robin Reid, MD
Hematology & Oncology · Rochester, NYNPI 1356583355
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 23 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in NY, where the typical reported total is $1,337.
Across 23 payments — averaging $20.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$103
- Johnson & Johnson$86
- Sanofi$62
- Bristol Myers Squibb$61
- Amgen$48
- GSK$26
- plus $89 from 5 others
What the payments were for
- Food & beverage$46197%
- Education$153%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 7 | $103 |
| Johnson & Johnson | 4 | $86 |
| Sanofi | 1 | $62 |
| Bristol Myers Squibb | 3 | $61 |
| Amgen | 2 | $48 |
| GSK | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Merck | 1 | $20 |
| AstraZeneca | 1 | $20 |
| Astellas Pharma US Inc | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
How this compares
$476 in reported general payments places this provider in the 30th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DopteletAvatrombopag Maleate | 12 | $176,330 |
| PegasysPeginterferon Alfa-2a | 12 | $47,266 |
| EliquisApixaban | 16 | $25,169 |
| Exemestane | 15 | $2,052 |
| Anastrozole | 127 | $1,975 |
| Tamoxifen Citrate | 37 | $1,329 |
| Letrozole | 28 | $505 |
| Acyclovir | 22 | $220 |
| Prochlorperazine Maleate | 24 | $189 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 11 | $101 |
| Prednisone | 11 | $35 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Rochester
- Alex SpyropoulosRochester$633K
- Adrienne VictorRochester$143K
- Brea LipeRochester$129K
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.